Market Intelligence, Clinical Progress, and High-Purity Reagents for Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), and Head & Neck Squamous Cell Carcinoma (HNSCC) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EGFR drug discovery. From 4th-generation TKI resistance profiling to next-generation ADC internalization assays—select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutants) | EGFR ECD-Fc / L858R / T790M / Exon19del / C797S Mutant Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View EGFR Products |
| Gene Delivery | EGFR Full-Length ORF Lentivirus For stable Ba/F3 or CHO cell line construction. Preserves native conformation for functional assays. |
View EGFR Products |
| Benchmark Antibodies | Anti-EGFR (Cetuximab / Panitumumab / Amivantamab Biosimilar Sequences) Recombinant positive controls for binding/blocking assays. |
View EGFR Products |
| Validation Tool | EGFR siRNA Set (3 specific duplexes) For knockdown verification and assay specificity controls. |
View EGFR Products |
| Related Target: MET | HGF Receptor (c-Met) Primary bypass resistance mechanism; Amivantamab co-target. |
View MET Products |
| Related Target: HER2 | ERBB2 / HER2 Heterodimerization partner; critical for bypass resistance screening. |
View HER2 Products |
| Related Target: HER3 | ERBB3 / HER3 Alternative dimerization partner for compensatory signaling. |
View HER3 Products |
| Related Target: KRAS | KRAS Downstream signaling node and major resistance mechanism. |
View KRAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 4th-Gen TKI Resistance Profiling (C797S/T790M Compound Mutants) | Purified double-mutant proteins (L858R/T790M/C797S) with Theoretical MW validation; strictly controlled endotoxin for cellular kinase assays. |
| ADC Internalization Efficiency | HEK293-expressed ECD-Fc preserves native glycosylation patterns critical for antibody recognition; available in Alexa488/647 labeled formats for flow-based uptake quantification. |
| Cross-Species Toxicity Evaluation (Cyno vs Mouse) | Human/Cynomolgus/Mouse ortholog protein panel (>95% purity) with sequence identity mapping to predict epitope conservation. |
| HER Family Selectivity (Off-target Safety) | Homologous ERBB panel (EGFRvIII, HER2, HER3, HER4) with mass-spec verified specificity for counter-screening. |
| Exon 20 Insertion Drugability | Custom Exon20 insertion mutant proteins (e.g., D770insNPG) with correct folding confirmed by conformational antibody binding. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) strictly sequence verified. |
| False Positives in Cell Assays | Validated siRNA included for rigorous specificity and knockdown checks. |
Live EGFR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The EGFR therapeutic landscape is transitioning from single-agent kinase inhibition to precision combination strategies. While 3rd-generation TKIs (Osimertinib) dominate 1st-line NSCLC, the emergence of C797S-mediated resistance and EGFR exon 20 insertions has catalyzed development of 4th-generation allosteric inhibitors and bispecific antibodies. Simultaneously, the industry is witnessing a modality shift toward Antibody-Drug Conjugates (ADCs) and MET-EGFR bispecifics (e.g., Amivantamab), leveraging internalization-dependent payload delivery and simultaneous blockade of bypass signaling. The next wave of R&D focuses on brain-penetrant scaffolds for CNS metastases and rational combinations with KRAS inhibitors in colorectal cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| 4th Gen TKI | Blueprint Medicines (BLU-945), Cullinan (CLN-081) | C797S+ NSCLC, Brain Metastases | Compound Mutant Kinase Assay (Need purified L858R/T790M/C797S substrate) |
| ADC | Mirati Therapeutics, AbbVie (ABBV-221) | EGFR-high Solid Tumors (HNSCC) | Internalization & Trafficking Assay (Need pH-sensitive labeled ECD proteins) |
| Bispecific (EGFRxcMET) | Janssen (Amivantamab), BioNTech | Exon20 Ins NSCLC, Osi-Resistant | Heterodimer Binding Validation (Need full-length lentivirus for native conformation) |
| Allosteric Inhibitor | EiRIS (EAI-001), JNU-1721 | Triple Mutant NSCLC | Conformational Selectivity Assay (Need WT vs Mutant conformational panels) |
| mAb (3rd Gen) | Genmab, Daiichi Sankyo | CRC (RAS WT), HNSCC | ADCC Effector Function (Need high-purity ECD-Fc for FcγR binding) |
| PROTACs / Degraders | C4 Therapeutics, Arvinas | TKI-Resistant NSCLC | Ternary Complex Formation (Need Specific Mutant EGFR Constructs) |